Get the Stockscreener App
0.1065
0.00%
0.00
After Hours:
.10
-0.0065
-6.10%
Quince Therapeutics Inc stock is traded at $0.1065, with a volume of 15.19M.
It is up +0.00% in the last 24 hours and down -46.75% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$0.1065
Open:
$0.106
24h Volume:
15.19M
Relative Volume:
0.27
Market Cap:
$5.93M
Revenue:
-
Net Income/Loss:
$-56.98M
P/E Ratio:
-0.0874
EPS:
-1.2189
Net Cash Flow:
$-38.98M
1W Performance:
+4.11%
1M Performance:
-46.75%
6M Performance:
-93.34%
1Y Performance:
-92.45%
1-Day Range:
$0.1009
$0.1065
1-Week Range:
$0.0952
$0.1229
52-Week Range:
$0.088
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.1065 | 5.93M | 0 | -56.98M | -38.98M | -1.2189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
What sparked Quince Therapeutics (QNCX) stock to rise 53% after hours - MSN
Can Quince Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Selloffs & Entry Point Confirmation Signals - Naître et grandir
Aug PreEarnings: Is now the right time to enter Quince Therapeutics IncTrend Reversal & Community Trade Idea Sharing Platform - baoquankhu1.vn
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts - Defense World
Trading Recap: Is Quince Therapeutics Inc stock overvalued or fairly priced2025 Technical Overview & Verified Short-Term Plans - baoquankhu1.vn
QNCX Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
QNCX Technical Analysis & ETF Price Forecast - Intellectia AI
What Does the Market Think About Quince Therapeutics Inc? - Benzinga
Can Quince Therapeutics Inc. stock surprise with earnings upsideJuly 2025 WrapUp & Consistent Return Investment Signals - mfd.ru
Published on: 2026-02-20 10:05:26 - mfd.ru
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours - Sahm
Market Overview: What is the long term forecast for Warner Music Group Corp stock2025 Earnings Impact & Stepwise Trade Signal Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Quince Therapeutics stock plunges as filing shows reverse merger plans, bankruptcy risks - MSN
Sell Signal: Is now the right time to enter Quince Therapeutics IncEarnings Overview Report & Smart Money Movement Tracker - baoquankhu1.vn
Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort - The Globe and Mail
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Sahm
3 Penny Stocks to Watch Now, 2/13/26 - TipRanks
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Quince Therapeutics engages LifeSci Capital for strategic alternatives - marketscreener.com
Quince Therapeutics Inc (QNCX) Stock Price, Quote, News & History - Benzinga
Quince Therapeutics stock plummets after revealing strategic alternatives By Investing.com - Investing.com Canada
Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com
Quince TherapeuticsOn Feb 9, Engaged Lifesci Capital For Strategic AlternativesSEC Filing - TradingView
Best Penny Stocks To Watch Now – February 10th - Defense World
Small Cap Stocks To Follow Now – February 10th - Defense World
Does Quince Therapeutics Inc. align with a passive investing strategyTrade Entry Summary & Free Weekly Watchlist of Top Performers - mfd.ru
Quince Therapeutics Stock Extends Rally On Strategic Review - Benzinga
Quince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors Emerge - MEXC
Quince Therapeutics (QNCX) Stock Surges 300% on Strategic Alternative Plans - parameter.io
QNCX Stock Price and Chart — NASDAQ:QNCX - TradingView
Quince Therapeutics (QNCX) Stock: What’s Behind the 300% Rally? - CoinCentral
Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive - TechStock²
Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
Why is Quince Therapeutics stock soaring Tuesday? - MSN
QNCX (Quince Therapeutics) NASDAQ intraday up 182.82% to $0.39: watch strategic-review momentum - Meyka
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Mena FN
Why Is Quince Therapeutics Stock Soaring Tuesday? - Benzinga
Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move - TechStock²
Quince Therapeutics Exploring Strategic Alternatives; Stock Soars - Nasdaq
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):